Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus

In the paper

“The decreases of HbA 1c in those using BGM were similar to the decreases in comparably treated people who did not use BGM.”

What the sources say

• Partly supported

  The Glycaemic control measured by HbA1c section reports that several studies found HbA1c improvements in both groups without a statistically significant difference. But the Subgroup analyses section reports a statistically significant 0.3-percentage-point greater decrease with self-monitoring at up to six months, so the unqualified statement that the decreases were similar overstates the review's findings. (LLM, conf=0.88)

  cites [111] Malanda, 2012, Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin, Cochrane Database Syst Rev sourceExperimental — accuracy not yet measured
• Supported

  The Discussion reports HbA1c decreases of 0.88% in the self-monitoring group and 0.69% in the comparator group, supporting the description of broadly similar decreases. It also notes a small additional reduction with self-monitoring, so “similar” should not be read as “identical.” (LLM, conf=0.88)

  cites [112] Farmer, 2012, Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetes, BMJ source
• ?Not checked — no full text of the sourcecites [113] Machry, 2018, Self-monitoring blood glucose improves glycemic control in type 2 diabetes without intensive treatment: a systematic review and meta-analysis, Diabetes Res Clin Pract source
• Disputed

  In “Trials Comparing SMBG with no SMBG” (p. 3), the paper reports a statistically significant greater reduction in HbA1c with self-monitoring than without it (−0.17 percentage points in the full dataset). The Discussion (p. 5) likewise calls the reduction small but significant, rather than similar between groups. (LLM, conf=0.88)

  Checked by a reasoning model — may be wrong.

  cites [114] Mannucci, 2018, Effects of structured versus unstructured self-monitoring of blood glucose on glucose control in patients with non-insulin-treated type 2 diabetes: a meta-analysis of randomized controlled trials, J Diabetes Sci Technol sourceExperimental — accuracy not yet measured

In the paper

“The presence of multiple islet autoantibodies (IAA, GADA, IA-2A/IA-2bA, or ZnT8A) is associated with a risk of type 1 diabetes of >90% (408,422,423).”

What the sources say

• Disputed

  The Results section (Children With Multiple Islet Autoantibodies; page unavailable) confirms that multiple autoantibodies are associated with high risk, but reports progression of 69.7% at 10 years and 84.2% at 15 years—not greater than 90%. Adding ZnT8 autoantibodies did not substantially change the progression estimates in the cohorts where they were measured. (LLM, conf=0.88)

  Checked by a reasoning model — may be wrong.

  cites [408] Ziegler, 2013, Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children, JAMA sourceExperimental — accuracy not yet measured
• Disputed

  The Results (Number and type of autoantibodies; page unavailable) report five-year diabetes incidences of 29% for participants with two autoantibodies and 31% for those with more than two. The Discussion says risk varies substantially after screening and that progression was questionable for a considerable number even with more than two autoantibodies. These five-year estimates do not establish lifetime risk, but the paper does not support the unqualified >90% risk attributed to it. (LLM, conf=0.83)

  Checked by a reasoning model — may be wrong.

  cites [422] Jacobsen, 2020, The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening, Diabetologia sourceExperimental — accuracy not yet measured
• Partly supported

  The Results report a higher 15-year type 1 diabetes risk with multiple autoantibodies, but the risk exceeded 90% only in some groups: it was 92% with three autoantibodies at seroconversion, versus 85% with two. Table 2 also shows that risk varied by age at development of multiple autoantibodies. The unqualified >90% figure is therefore not supported; ZnT8A was measured but excluded from the primary analyses. (LLM, conf=0.91)

  cites [423] Anand, 2021, Islet autoimmunity and HLA markers of presymptomatic and clinical type 1 diabetes: joint analyses of prospective cohort studies in Finland, Germany, Sweden, and the U.S, Diabetes Care sourceExperimental — accuracy not yet measured

In the paper

“Notwithstanding this recommendation, the evidence that population screening for hyperglycemia and subsequent prevention efforts will provide long-term benefit is inconsistent (27).”

What the sources say

• Partly supported

  The Discussion (page unavailable) says evidence that diabetes prevention reduces long-term vascular complications is inconsistent. The paper assesses prevention studies, not population screening for hyperglycemia followed by prevention efforts, so it does not establish the claim for that broader strategy. (LLM, conf=0.88)

  cites [27] Nathan, 2019, Does diabetes prevention translate into reduced long-term vascular complications of diabetes?, Diabetologia sourceExperimental — accuracy not yet measured

In the paper

“FPG increases with increasing age beginning in the third to fourth decade (97,98).”

What the sources say

• Supported

  In “Normal” fasting blood glucose levels, the paper states that fasting plasma glucose tends to rise with age. Table 2 shows the mean increasing from ages 20–29 to 30–39 and continuing upward in older groups, consistent with a rise beginning in the third to fourth decade. (LLM, conf=0.90)

  cites [97] Tchobroutsky, 1991, Blood glucose levels in diabetic and non-diabetic subjects, Diabetologia source
• Supported

  The Glucose homoeostasis section states that fasting plasma glucose rises by approximately 0.055 mmol/L per decade, beginning as early as the fourth decade of life. This supports the citing sentence’s description of an age-related increase beginning in the third to fourth decade. (LLM, conf=0.94)

  cites [98] van den Beld, 2018, The physiology of endocrine systems with ageing, Lancet Diabetes Endocrinol source

In the paper

“Careful evaluation over several consecutive days in normoglycemic individuals revealed that biological variation of FPG (mean glucose of 4.9 mmol/L [88 mg/dL]) exhibited within-and between-subject CVs of 4.8% to 6.1% and 7.5% to 7.8%, respectively (90)(91)(92).”

What the sources say

• ?Not checked — no full text of the sourcecites [90] Widjaja, 1999, Within- and between-subject variation in commonly measured anthropometric and biochemical variables, Clin Chem source
• Partly supported

  The Abstract reports test–retest variation in fasting glucose among people with normal glucose tolerance. It does not give the claimed mean of 4.9 mmol/L, the within- and between-subject CV ranges, or an evaluation over several consecutive days; searches for those figures and terms found no supporting passage. (LLM, conf=0.78)

  cites [91] Mooy, 1996, Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study, Diabetologia sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [92] Sebastián-Gámbaro, 1997, Intra- and inter-individual biological variability data bank, Eur J Clin Chem Clin Biochem

In the paper

“Measurement of FPG in 246 normal and 80 previously undiagnosed individuals with diabetes revealed mean intraindividual CVs of 4.8% and 7.1%, respectively (91).”

What the sources say

• ?Could not verify

  The available Abstract passage discusses fasting-glucose test–retest variation in people with normal glucose tolerance, but gives no mean intraindividual CVs. Searches for 246, 80, 4.8%, and 7.1% found no passage verifying the sample sizes or the values for either group. (LLM, conf=0.72)

  cites [91] Mooy, 1996, Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study, Diabetologia sourceExperimental — accuracy not yet measured

In the paper

“Glucose homeostasis is impaired with aging.”

What the sources say

• Supported

  The “Normal” fasting blood glucose levels section reports that fasting glucose in apparently non-diabetic subjects tends to rise with age. The “Normal” post-prandial blood glucose levels section also reports that post-meal glucose rises with age. Together, these support the broad paraphrase about age-related impairment of glucose homeostasis. (LLM, conf=0.88)

  cites [97] Tchobroutsky, 1991, Blood glucose levels in diabetic and non-diabetic subjects, Diabetologia source
• Supported

  The Glucose homoeostasis section states that glucose homoeostasis tends towards disequilibrium with increasing chronological age. It also reports gradual increases in fasting and post-challenge glucose concentrations, supporting the citing sentence’s broad paraphrase. (LLM, conf=0.94)

  cites [98] van den Beld, 2018, The physiology of endocrine systems with ageing, Lancet Diabetes Endocrinol source

In the paper

“For example, the meta-analysis by Farmer et al. (112) found that the mean pooled reduction in HbA 1c was 0.88% in BGMassigned groups and 0.69% in the usual care groups.”

What the sources say

• Supported

  The Discussion reports a mean pooled HbA1c reduction of 0.88% in the self-monitoring intervention group and 0.69% in the comparator group across the trials. These are the values and groups attributed to Farmer et al. in the citing sentence. (LLM, conf=0.95)

  cites [112] Farmer, 2012, Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetes, BMJ source

In the paper

“Use of meters that meet the current ISO standard reduced the financial consequences of inaccuracy of glucose meters by more than £178 ($238) per patient-year.”

What the sources say

• Partly supported

  The Results (page unavailable) estimate £235 less inaccuracy-related cost per patient-year for an average meter meeting ISO 15197:2013 than for one failing ISO 15197:2003, which supports a reduction greater than £178 for that comparison. But the £178 figure itself compares meters failing and meeting the older 2003 standard; the paper reports modeled cost comparisons, not an observed reduction from using compliant meters. Our copy does not report the $238 figure. (LLM, conf=0.83)

  cites [128] Fortwaengler, 2018, The financial impact of inaccurate blood glucose monitoring systems, J Diabetes Sci Technol sourceExperimental — accuracy not yet measured

In the paper

“Meta-analyses also reported that, by 1 year of use of BGM, the improvements in HbA 1c seen at earlier time points were lost (111,113).”

What the sources say

• Partly supported

  The Main results report a significant HbA1c decrease at up to six months but a statistically non-significant decrease at 12 months in patients whose diabetes duration was at least one year. The Subgroup analyses also report a significant decrease at 12 months in newly diagnosed patients. The claim captures the first finding but omits that qualification and describes a non-significant result as improvements being lost. (LLM, conf=0.86)

  cites [111] Malanda, 2012, Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin, Cochrane Database Syst Rev sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [113] Machry, 2018, Self-monitoring blood glucose improves glycemic control in type 2 diabetes without intensive treatment: a systematic review and meta-analysis, Diabetes Res Clin Pract source

In the paper

“The study found no clinically or statistically significant differences at 1 year in glycemic control (as assessed by HbA 1c ) or health-related quality of life between patients who performed BGM, with or without enhanced feedback, and those who did not.”

What the sources say

• Supported

  Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [115] Young, 2017, Glucose self-monitoring in non–insulin-treated patients with type 2 diabetes in primary care settings: a randomized trial, JAMA Intern Med source

In the paper

“In a 2017 study, however, only 2 of 17 commercial meters intended for home BGM use met the ISO standard (125).”

What the sources say

• Partly supported

  The Results (‘Accuracy Based on ISO Criteria’) report that 2 of 17 meters met the ISO 2013 numerical accuracy criteria in this study, while 7 met the ISO 2003 criteria. The Discussion cautions that testing did not follow the ISO protocol, so the study does not establish that only two meters met an ISO standard under standard testing conditions. (LLM, conf=0.90)

  cites [125] Ekhlaspour, 2017, Comparative accuracy of 17 point-of-care glucose meters, J Diabetes Sci Technol sourceExperimental — accuracy not yet measured

In the paper

“The anatomical site from which skin puncture samples are obtained influences results: Use of blood from so-called alternate sites (such as forearm or thigh rather than fingertip) for testing may exhibit a temporal lag between the circulating and measured concentrations of glucose when blood glucose is changing in vivo (117).”

What the sources say

• Supported

  Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [117] Ellison, 2002, Rapid changes in postprandial blood glucose produce concentration differences at finger, forearm, and thigh sampling sites, Diabetes Care source

In the paper

“Meters that are designed for professional use have been shown in published studies to be accurate on samples of whole blood (129-131).”

What the sources say

• Supported

  The Impact Statement (page unavailable) describes the ACCU-CHEK Inform II as a point-of-care system intended to measure glucose in whole blood in hospital settings. The Sample Collection and Discussion sections (pages unavailable) report testing whole-blood samples from critically ill patients and finding that venous and neonatal heel-stick samples met the study’s accuracy criteria. This study supports the citing sentence as one example, although performance varied by sample type. (LLM, conf=0.90)

  cites [129] Nichols, 2021, A multicenter evaluation of a point-of-care blood glucose meter system in critically ill patients, J Appl Lab Med source
• Supported

  The Methods describe testing a point-of-care glucose meter on whole-blood aliquots, and the Results report that its measurements met the stated accuracy criteria. The Conclusions find acceptable analytic accuracy for use in critically ill patients. This paper supports the citing sentence as one example of such a study; its tests used venous whole blood. (LLM, conf=0.91)

  cites [130] Mitsios, 2013, Analytic evaluation of a new glucose meter system in 15 different critical care settings, J Diabetes Sci Technol source
• ?Not checked — no full text of the sourcecites [131] Karon, 2015, Impact of glucose meter error on glycemic variability and time in target range during glycemic control after cardiovascular surgery, J Diabetes Sci Technol source

In the paper

“The role of BGM in individuals with type 2 diabetes who are treated with only basal insulin or no insulin has generated considerable controversy (109).”

What the sources say

• Partly supported

  The Recommendations section says the optimal use of self-monitoring in non–insulin-treated type 2 diabetes is unclear and that trials have questioned its clinical utility and cost-effectiveness. It says monitoring may be useful for people using less-frequent insulin injections, but does not describe comparable controversy specifically for basal-only insulin. (LLM, conf=0.83)

  cites [109] American Diabetes Association, 2011, Standards of medical care in diabetes—2011, Diabetes Care sourceExperimental — accuracy not yet measured

In the paper

“However, except for the potential use of BGM in people with type 2 diabetes using insulin, BGM likely adds cost without benefit (110).”

What the sources say

• Partly supported

  The Abstract and Discussion (page not available in our copy) report higher costs and no clinically significant benefit from self-monitoring compared with standardised usual care. But the study concerns reasonably well-controlled people with non-insulin-treated type 2 diabetes; the Discussion cautions that its results may not apply to other groups. It does not establish the claim for everyone except those using insulin. (LLM, conf=0.88)

  cites [110] Simon, 2008, Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial, BMJ sourceExperimental — accuracy not yet measured

In the paper

“Analytical errors of meters that meet the 2013 ISO standard have only limited impact on the three outcome measures or on HbA 1c .”

What the sources say

• Supported

  The Discussion states that BG monitoring systems compliant with most conditions of ISO 15197 (2013) have only limited impact on HbA1c and the three other outcomes: severe hypoglycemia events, insulin use, and SMBG frequency. The claim paraphrases that conclusion; the paper describes compliance with most conditions rather than explicitly stating full compliance. (LLM, conf=0.90)

  cites [127] Campos-Náñez, 2017, Clinical impact of blood glucose monitoring accuracy: an in-silico study, J Diabetes Sci Technol source

In the paper

“Numerous interfering factors have been reported to influence the results of blood glucose meters (135,136).”

What the sources say

• ?Not checked — no full text of the sourcecites [135] Erbach, 2016, Interferences and limitations in blood glucose self-testing: an overview of the current knowledge, J Diabetes Sci Technol source
• Supported

  The Introduction states that glucose meters are subject to numerous interferences, including patient, environmental, and operational factors. The discussion following Table 3 adds that these interferences can produce misleading glucose measurements. (LLM, conf=0.94)

  cites [136] Tirimacco, 2013, Glucose meters—fit for clinical purpose, Clin Chem Lab Med source

In the paper

“Several sugars-notably maltose, galactose, and xylose-falsely increase results of some glucose meters.”

What the sources say

• ?Not checked — no full text of the sourcecites [139] Perera, 2011, The danger of using inappropriate point-of-care glucose meters in patients on icodextrin dialysis, Diabet Med source
• ?Not checked — no full text of the sourcecites [133] Ceriotti, 2015, Comparative performance assessment of point-of-care testing devices for measuring glucose and ketones at the patient bedside, J Diabetes Sci Technol source
• Partly supported

  The Discussion (page unavailable) says galactose and maltose increased readings on the Accu-Chek and FreeStyle meters at all three glucose levels tested. The paper does not report testing xylose, so it does not support that part of the claim. (LLM, conf=0.90)

  cites [140] Lv, 2013, Factors interfering with the accuracy of five blood glucose meters used in Chinese hospitals, J Clin Lab Anal sourceExperimental — accuracy not yet measured

In the paper

“A later study found a strong, continuous association of BGM frequency with improved glycemic control as measured by HbA 1c (150).”

What the sources say

• Partly supported

  The Results report a strong association between more frequent self-monitoring of blood glucose and lower HbA1c in all age groups. However, they also say the association appeared to level off at approximately 10 measurements per day, so “continuous” overstates the finding if it means improvement at every frequency. (LLM, conf=0.85)

  cites [150] Miller, 2013, Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants, Diabetes Care sourceExperimental — accuracy not yet measured

In the paper

“Monitoring of blood glucose less frequently than three to four times per day in adults and adolescents has been associated with less effective control of glycemia as measured by HbA 1c (150)(151)(152).”

What the sources say

• Supported

  The Results report that more frequent blood-glucose monitoring was strongly associated with lower HbA1c in every age group studied, including adolescents and adults. The Methods group monitoring frequencies as 0–2 and 3–4 times per day, consistent with the claim’s comparison. This is an association in people with type 1 diabetes, not evidence of causation. (LLM, conf=0.91)

  cites [150] Miller, 2013, Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants, Diabetes Care source
• Partly supported

  The Results report that more frequent monitoring was associated with lower HbA1c, and the Discussion specifies a marked improvement with 2–5 measurements per day among adolescents. The study covers children and adolescents, not adults, and does not establish a specific three-to-four-times-per-day threshold. (LLM, conf=0.88)

  cites [151] Ziegler, 2011, Frequency of SMBG correlates with HbA1c and acute complications in children and adolescents with type 1 diabetes, Pediatr Diabetes sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [152] Schütt, 2006, Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria, Exp Clin Endocrinol Diabetes source

In the paper

“A subsequent RCT specifically targeting adolescents and young adults, which included considerable education and support, showed that those randomized to rt-CGM had significantly reduced HbA 1c after 6 months compared with those randomized to BGM (175).”

What the sources say

• Supported

  Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [175] Laffel, 2020, Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: a randomized clinical trial, JAMA source

In the paper

“A subsequent international consensus defined targets for most of the measures on the AGP that would correspond to individualized HbA 1c targets (193).”

What the sources say

• Partly supported

  The Time in Ranges section (p. 10) sets personalized targets for time within, below, and above glucose ranges, and Standardization of CGM Data Presentation (p. 16) says the AGP incorporates core CGM metrics and targets. Relationship Between TIR and A1C (p. 14) gives approximate A1C values corresponding to time-in-range levels. The paper does not establish a correspondence between individualized HbA1c targets and most AGP measures; the stated A1C relationship is specifically for time in range. (LLM, conf=0.82)

  cites [193] Battelino, 2019, Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range, Diabetes Care sourceExperimental — accuracy not yet measured

In the paper

“Studies designed to establish correlations between blood and tear glucose concentrations are inconclusive from both human (243-245) and animal studies (246).”

What the sources say

• ?Not checked — no full text of the sourcecites [243] Baca, 2007, Tear glucose analysis for the noninvasive detection and monitoring of diabetes mellitus, Ocul Surf source
• Supported

  The paper’s introduction says disagreement continues about the correlation between human tear and blood glucose concentrations. Although its own fasting study found a significant correlation, the Abstract says larger population studies are needed to determine that relationship. The citing sentence assigns animal studies to a separate citation, so the animal portion is not attributed to this source. (LLM, conf=0.87)

  cites [244] Baca, 2007, Mass spectral determination of fasting tear glucose concentrations in nondiabetic volunteers, Clin Chem source
• ?Not checked — no full text of the sourcecites [245] Cha, 2014, Evaluation of commercial glucometer test strips for potential measurement of glucose in tears, Anal Chem source
• ?Not checked — no full text of the sourcecites [246] Peng, 2013, Evaluation of enzyme-based tear glucose electrochemical sensors over a wide range of blood glucose concentrations, Biosens Bioelectron source

In the paper

“Rates of several adverse neonatal outcomes (large-forgestational-age infants, newborn intensive care unit admissions, neonatal hypoglycemia) were lower in the group randomized to rt-CGM (184).”

What the sources say

• Supported

  The Discussion reports lower proportions of large-for-gestational-age infants, neonatal hypoglycaemia, and neonatal intensive care admissions among women randomised to CGM during early pregnancy. The Results specify that the intensive care admissions lasted more than 24 hours and that the hypoglycaemia required intravenous dextrose; these are the outcomes summarised in the claim. (LLM, conf=0.95)

  cites [184] Feig, 2017, Continuous Glucose Monitoring in Pregnant Women with Type 1 Diabetes (CONCEPTT): a multicentre international randomised controlled trial, Lancet source

In the paper

“Some secondary outcomes, including risks of shoulder dystocia and/or birth injury and preeclampsia, were also associated with maternal glycemia (257).”

What the sources say

• Partly supported

  The Results and Comment sections report that preeclampsia became more frequent as maternal glucose increased, although the association weakened after adjustment for C-peptide. Our copy does not report an association between maternal glycemia and shoulder dystocia or birth injury; searches for those outcomes found no supporting passage. No page numbers were provided. (LLM, conf=0.88)

  cites [257] Yogev, 2010, Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: preeclampsia, Am J Obstet Gynecol sourceExperimental — accuracy not yet measured

In the paper

“In addition, women with GDM have a considerably increased risk of developing type 2 diabetes after pregnancy (273), and the Diabetes Prevention Program (DPP) found that progression to diabetes can be delayed or prevented by intervention (274); thus, long-term follow-up is important.”

What the sources say

• Supported

  The Abstract reports that, in the DPP cohort as a whole, intensive lifestyle intervention reduced diabetes incidence by 58% and metformin by 31% compared with placebo. It also reports reduced progression to diabetes with both interventions among women with a history of GDM, supporting the citing sentence's broader statement that intervention can delay or prevent progression. (LLM, conf=0.94)

  cites [274] Ratner, 2008, Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions, J Clin Endocrinol Metab source

In the paper

“Since the cumulative risk of progression to diabetes after GDM is linear over time (reaching 50% to 60% [273,275]), women should be evaluated every 1 to 3 years with any recommended test of glycemia, e.g., annual HbA 1c , annual FPG, or triennial 75-g OGTT (with nonpregnant cutoffs) (251).”

What the sources say

• Partly supported

  The Discussion (Comparison with other studies; page unavailable) says cumulative incidence increased steadily over time, which supports an increasing trend but does not establish that it was linear. The Results (Meta-analysis; page unavailable) report a pooled cumulative incidence of 16.15% in studies with more than 10 years of follow-up, not the claimed 50% to 60%. (LLM, conf=0.86)

  cites [273] Vounzoulaki, 2020, Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis, BMJ sourceExperimental — accuracy not yet measured
• Supported

  The Results (§3.3) report that estimated T2DM risk after GDM increased linearly with follow-up duration, reaching 48.64% at 40 years and 58.27% at 50 years. These long-term modeled estimates support the cited 50%–60% range; the separate screening recommendation is not attributed to this source. (LLM, conf=0.93)

  cites [275] Li, 2020, Incidence rate of type 2 diabetes mellitus after gestational diabetes mellitus: a systematic review and meta-analysis of 170,139 women, J Diabetes Res source

In the paper

“Follow-up of the children in both these studies at 4 to 5 (264-266) and 7 years of age (267), respectively, failed to observe differences in limited indicators of child adiposity between children of mothers with treated GDM and those with untreated GDM.”

What the sources say

• ?Could not verify

  The secondary outcomes section reports infant measurements at birth and explicitly says long-term follow-up is needed. A search for adiposity outcomes at ages 4–5 and 7 found no such follow-up results in our copy, so this paper cannot verify the claimed absence of differences at those ages. (LLM, conf=0.76)

  cites [264] Crowther, 2005, Effect of treatment of gestational diabetes mellitus on pregnancy outcomes, N Engl J Med sourceExperimental — accuracy not yet measured
• ?Could not verify

  The Results (Perinatal and Neonatal Outcomes; page unavailable) report birth weight and neonatal fat mass, not adiposity at ages 4–5 or 7. The Discussion says long-term follow-up studies are needed to determine whether treatment affects childhood outcomes. Searches for follow-up and childhood adiposity found no results at either age in our copy. (LLM, conf=0.78)

  cites [265] Landon, 2009, A multicenter, randomized trial of treatment for mild gestational diabetes, N Engl J Med sourceExperimental — accuracy not yet measured
• Partly supported

  The Conclusions report no reduction in BMI after treatment of mild GDM, supporting the null finding. But citation 267 is attached to the seven-year follow-up, whereas this paper measured children at ages 4–5; the Conclusions say its height-and-weight surveillance did not extend past age five. (LLM, conf=0.88)

  cites [266] Gillman, 2010, Effect of treatment of gestational diabetes mellitus on obesity in the next generation, Diabetes Care sourceExperimental — accuracy not yet measured
• Supported

  The citation to this paper is attached to the 7-year follow-up, not the separately cited 4–5-year study. The Results (Follow-up Data) report a mean follow-up age of about 7 years and no significant difference between treated and untreated groups in BMI-defined obesity or secondary obesity measures. (LLM, conf=0.92)

  cites [267] Landon, 2015, Mild gestational diabetes mellitus and long-term child health, Diabetes Care source

In the paper

“For example, comparison of glucose measured in samples collected in sodium fluoride-containing tubes kept in an ice-water slurry, as recommended (109), with those kept at room temperature increased the rate of diagnosis of GDM by 2.7-fold (277), entirely due to control of glycolysis.”

What the sources say

• ?Could not verify

  Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.

  cites [109] American Diabetes Association, 2011, Standards of medical care in diabetes—2011, Diabetes Care sourceExperimental — accuracy not yet measured
• Partly supported

  Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [277] Daly, 2016, Impact of implementing preanalytical laboratory standards on the diagnosis of gestational diabetes Mmellitus: a prospective observational study, Clin Chem sourceExperimental — accuracy not yet measured

In the paper

“Similarly, in 121 women screened for GDM with OGTTs, collecting samples in tubes containing citrate buffer doubled the diagnostic sensitivity for GDM compared with samples collected in sodium fluoridecontaining tubes (73).”

What the sources say

• Supported

  The study includes 121 women undergoing OGTT screening (To the Editor, p. 2). Its results report that citrate-fluoride-EDTA tubes doubled diagnostic sensitivity for GDM compared with customary fluoride-EDTA tubes, from 42.0% to 86.0% (Letters to the Editor, p. 2). (LLM, conf=0.94)

  cites [73] Daly, 2016, Comparison of citrate-fluoride-EDTA with fluoride-EDTA additives to stabilize plasma glucose measurements in women being screened during pregnancy with an oral glucose tolerance test: a prospective observational study, Clin Chem source

In the paper

“In addition, women with GDM have a considerably increased risk of developing type 2 diabetes after pregnancy (273), and the Diabetes Prevention Program (DPP) found that progression to diabetes can be delayed or prevented by intervention (274); thus, long-term follow-up is important.”

What the sources say

• Supported

  The Results > Meta-analysis section reports a pooled relative risk of 9.51 for type 2 diabetes in women with previous GDM compared with controls. The Discussion > Conclusions likewise describes a nearly 10-fold increased risk after a GDM pregnancy. The separate DPP claim is attributed to another citation and is not part of this verdict. (LLM, conf=0.95)

  cites [273] Vounzoulaki, 2020, Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis, BMJ source

In the paper

“The results clearly demonstrate that maternal glycemia is associated with immediate and long-term adverse outcomes for both mother and offspring.”

What the sources say

• Partly supported

  The Abstract (page unavailable) says the original HAPO Study linked pregnancy glucose levels to perinatal outcomes, while the follow-up examined long-term outcomes in mothers and children. The Discussion (page unavailable) reports a long-term association with maternal glucose disorders and some childhood adiposity measures, but says the association with childhood overweight or obesity was not statistically significant. The claim overstates these findings by saying the follow-up results clearly demonstrate immediate and long-term adverse outcomes for both mother and offspring. (LLM, conf=0.86)

  cites [268] Lowe, 2018, Association of gestational diabetes with maternal disorders of glucose metabolism and childhood adiposity, JAMA sourceExperimental — accuracy not yet measured
• Partly supported

  The Conclusions report that maternal hyperglycemia during pregnancy was associated with a higher risk of impaired glucose tolerance in offspring at ages 10–14. They also mention a higher later risk of type 2 diabetes in mothers with GDM, but this study does not demonstrate immediate adverse outcomes for both mother and offspring. The claim therefore extends beyond what its results establish. (LLM, conf=0.88)

  cites [269] Lowe, 2019, Hyperglycemia and adverse pregnancy outcome follow-up study (HAPO FUS): maternal gestational diabetes mellitus and childhood glucose metabolism, Diabetes Care sourceExperimental — accuracy not yet measured

In the paper

“Semiquantitative urine glucose monitoring does not accurately reflect plasma glucose concentration (295).”

What the sources say

• Supported

  The “Urine glucose testing” section says urine glucose testing provides only a rough estimate of prevailing blood glucose levels. It also explains that renal-threshold variation, urine concentration, and the time since the last voiding limit how accurately a urine result reflects blood glucose. (LLM, conf=0.94)

  cites [295] Goldstein, 2004, Tests of glycemia in diabetes, Diabetes Care source

In the paper

“since AcAc and acetone may increase as bOHB falls during successful therapy (295,298).”

What the sources say

• Partly supported

  The Urine ketone testing section says the relative proportions of β-hydroxybutyrate, acetoacetate, and acetone vary, and that urine ketones can persist during recovery from ketoacidosis after blood ketones fall. It does not say that acetoacetate and acetone may increase specifically as β-hydroxybutyrate falls during successful therapy; no page number is available in our copy. (LLM, conf=0.77)

  cites [295] Goldstein, 2004, Tests of glycemia in diabetes, Diabetes Care sourceExperimental — accuracy not yet measured
• Partly supported

  The Diagnosis section (page unavailable) says β-hydroxybutyrate should decrease following fluid and intravenous insulin treatment. It discusses acetoacetate testing but does not say acetoacetate increases during successful therapy, and the searched passages do not report an increase in acetone. (LLM, conf=0.84)

  cites [298] Dhatariya, 2020, Diabetic ketoacidosis, Nat Rev Dis Primers sourceExperimental — accuracy not yet measured

In the paper

“Importantly, this reagent does not measure bOHB (295,304).”

What the sources say

• Supported

  The Urine ketone testing section states that commercially available nitroprusside-based ketone tests do not detect β-hydroxybutyric acid (β-hydroxybutyrate). This directly supports the claim about the reagent. (LLM, conf=0.95)

  cites [295] Goldstein, 2004, Tests of glycemia in diabetes, Diabetes Care source
• ?Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  cites [304] Sacks, 2023, Diabetes mellitus

In the paper

“For example, in a large Chinese cohort, many women with FPG in the first trimester above the IADPSG threshold for GDM did not have GDM when tested later in gestation (279).”

What the sources say

• Partly supported

  The Results report that only 39.8% of women with FPG ≥5.10 mmol/L at the first prenatal visit were diagnosed with GDM at 24–28 weeks, supporting the main point. But the paper does not restrict those first-visit measurements to the first trimester; its Conclusions explicitly distinguish “first prenatal visit” from “early pregnancy” because visit timing varied. (LLM, conf=0.87)

  cites [279] Zhu, 2013, Evaluation of the value of fasting plasma glucose in the first prenatal visit to diagnose gestational diabetes mellitus in China, Diabetes Care sourceExperimental — accuracy not yet measured

In the paper

“bOHB, the predominant ketone body in DKA, is not detected.”

What the sources say

• Supported

  The Urine ketone testing section says that in diabetic ketoacidosis, the ratio of β-hydroxybutyrate to acetoacetate may rise to 6:1 or greater, supporting its description as the predominant ketone body. The same section says that none of the commercially available urine ketone tests described detect β-hydroxybutyric acid. The supplied passages do not give page numbers. (LLM, conf=0.94)

  cites [295] Goldstein, 2004, Tests of glycemia in diabetes, Diabetes Care source
• Supported

  The Diagnosis section identifies β-hydroxybutyrate as “the main ketone in DKA.” It also says the nitroprusside test does not detect it, matching the cited sentence’s context. (LLM, conf=0.95)

  cites [298] Dhatariya, 2020, Diabetic ketoacidosis, Nat Rev Dis Primers source

In the paper

“One small study in children with DKA found that use of a POC assay for bOHB decreased time to conversion from intravenous to subcutaneous insulin.”

What the sources say

• Partly supported

  In 'During treatment' (page not available), the proposed point-of-care hydroxybutyrate end-point was reached a median of 11 hours before the urine-ketone end-point in 28 pediatric DKA episodes. But the study states that hydroxybutyrate results did not inform clinical decisions; it therefore shows a potential for earlier conversion, not that using the assay actually decreased time to conversion. (LLM, conf=0.88)

  cites [308] Noyes, 2007, Hydroxybutyrate near-patient testing to evaluate a new end-point for intravenous insulin therapy in the treatment of diabetic ketoacidosis in children, Pediatr Diabetes sourceExperimental — accuracy not yet measured

In the paper

“The glycemic thresholds for the diagnosis of GDM in the second and third trimesters may not be appropriate for early pregnancy because FPG normally declines in early pregnancy (282,283).”

What the sources say

• Supported

  The Discussion says that using FPG as a basis for diagnosing GDM early in pregnancy may be inappropriate because FPG decreases as gestational age increases. The Introduction also notes controversy over applying an FPG threshold of ≥5.10 mmol/L before 24 weeks. No page numbers are provided in our copy. (LLM, conf=0.90)

  cites [282] Wei, 2019, Value of fasting plasma glucose to screen gestational diabetes mellitus before the 24th gestational week in women with different pre-pregnancy body mass index, Chin Med J (Engl) source
• ?Not checked — no full text of the sourcecites [283] Mills, 1998, Physiological reduction in fasting plasma glucose concentration in the first trimester of normal pregnancy: the diabetes in early pregnancy study, Metabolism source

In the paper

“Other studies suggest that biomarkers such as CD59 (287) or serum secreted frizzlerelated protein-5 (288) may be useful in early identification of women in whom GDM will be identified later in pregnancy.”

What the sources say

• Partly supported

  The Results and Conclusions report that plasma glycated CD59 distinguished women with GDM and could be useful for screening. But the Research Design and Methods say samples were collected during routine screening at about 26 weeks, and the Conclusions identify detection earlier in pregnancy as a question for future studies. This paper therefore does not establish early identification of women whose GDM would be identified later in pregnancy. (LLM, conf=0.88)

  cites [287] Ghosh, 2017, Plasma glycated CD59, a novel biomarker for detection of pregnancy-induced glucose intolerance, Diabetes Care sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [288] Oztas, 2016, Prediction of gestational diabetes mellitus by first trimester serum secreted frizzle-related protein-5 levels, J Matern Fetal Neonatal Med source

In the paper

“False-positive results have been reported with highly colored urine and in the presence of several sulfhydrylcontaining drugs, including angiotensinconverting enzyme inhibitors (301).”

What the sources say

• Partly supported

  The Discussion (section 7; page not provided) says sulphydryl drugs such as captopril could cause false-positive urine ketone results. It does not identify highly colored urine as a cause or explicitly describe captopril as an angiotensin-converting enzyme inhibitor. (LLM, conf=0.85)

  cites [301] Brooke, 2016, Evaluation of the accuracy of capillary hydroxybutyrate measurement compared with other measurements in the diagnosis of diabetic ketoacidosis: a systematic review, Int J Environ Res Public Health sourceExperimental — accuracy not yet measured

In the paper

“Thus, assay methods for ketones that do not include measurement of bOHB may provide misleading clinical information by underestimating total ketone body concentration (295,299).”

What the sources say

• Supported

  The Urine ketone testing section says that commercially available nitroprusside tests do not detect β-hydroxybutyric acid, although it can predominate among ketone bodies in diabetic ketoacidosis. The Blood versus urine ketones section also reports elevated plasma β-hydroxybutyric acid in patients whose urine nitroprusside tests did not show ketones. Together, these passages support the warning that tests omitting βOHB can underestimate ketones and mislead clinically. (LLM, conf=0.92)

  cites [295] Goldstein, 2004, Tests of glycemia in diabetes, Diabetes Care source
• Supported

  The Controversies and Recommendations section says the nitroprusside test principally measures acetoacetate rather than BOHB. Because BOHB predominates in diabetic ketoacidosis, the paper says this test can initially underestimate ketonemia, supporting the claim in that clinical context. (LLM, conf=0.91)

  cites [299] Kilpatrick, 2022, Controversies around the measurement of blood ketones to diagnose and manage diabetic ketoacidosis, Diabetes Care source

In the paper

“Concentrations of these glycated proteins also reflect mean glycemia but over a much shorter time (15 to 30 days, reflecting the turnover of albumin) than GHb ( 60 to 90 days) (295,(311)(312)(313)(314)(315)(316).”

What the sources say

• Partly supported

  The “Glycated serum proteins” section says that albumin’s shorter turnover makes glycated serum proteins an index of glycemia over a shorter period than glycated hemoglobin. It does not give the claimed 15–30-day and 60–90-day windows; the “Glycated hemoglobin testing” section instead describes GHb as providing a glycemic history of the previous 120 days. (LLM, conf=0.86)

  cites [295] Goldstein, 2004, Tests of glycemia in diabetes, Diabetes Care sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [311] Bunn, 1981, Nonenzymatic glycosylation of protein: relevance to diabetes, Am J Med source
• Not checked yetcites [312] Goldstein, 1986, Glycated hemoglobin: methodologies and clinical applications, Clin Chem

In the paper

“Individuals with well-documented diabetic ketoacidosis (serum bicarbonate <15 mmol/L, arterial pH <7.3, plasma glucose >14.9 mmol/L [250 mg/dL]) generally have bOHB concentrations >2 mmol/L (299).”

What the sources say

• Supported

  In “Evidence for Diagnostic and Management Thresholds” (page unavailable), the paper reports a commonly adopted β-hydroxybutyrate cutoff of 3 mmol/L for DKA, based on patients diagnosed by other means and a later study of children and adults. That supports the citing sentence’s qualified statement that concentrations in documented DKA are generally above 2 mmol/L, though the paper does not use that exact cutoff. (LLM, conf=0.84)

  cites [299] Kilpatrick, 2022, Controversies around the measurement of blood ketones to diagnose and manage diabetic ketoacidosis, Diabetes Care source

In the paper

“Since hospitalization rates for DKA are increasing (310), further studies are needed to determine more optimal home testing strategies to detect impending ketonemia.”

What the sources say

• Supported

  The Results (Diabetic Ketoacidosis) report that U.S. adult inpatient DKA rates increased 75.4%, from 14.2 to 24.9 per 1,000 adults with diabetes, from 2009 to 2015. This supports the cited statement about increasing hospitalization rates, within that population and period. (LLM, conf=0.94)

  cites [310] Benoit, 2020, Trends in emergency department visits and inpatient admissions for hyperglycemic crises in adults with diabetes in the U.S., 2006–2015, Diabetes Care source

In the paper

“Careful phenotyping of subjects with OGTT supports an increase in HbA 1c with age, even after removing those with otherwise undiagnosed diabetes and people with impaired glucose tolerance from the study population (336).”

What the sources say

• ?Could not verify

  The Methods describe fasting-glucose measurements and analyses of diabetes and cardiovascular risk, not phenotyping by oral glucose tolerance test (OGTT). Neither the Results nor the additional passages found for age and impaired glucose tolerance report whether HbA1c rises with age after excluding those groups. The claim cannot be verified from our copy. (LLM, conf=0.76)

  cites [336] Selvin, 2010, Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults, N Engl J Med sourceExperimental — accuracy not yet measured

In the paper

“Population data show age-related increases in mean HbA 1c in people without diabetes of approximately 0.1% per decade after age 30 years (334,335).”

What the sources say

• Supported

  The Results report that, among nondiabetic participants, each additional year of age was associated with a 0.012-point increase in A1C in FOS and a 0.010-point increase in NHANES—approximately 0.1 percentage points per decade. The Methods include adults aged 25 and older in FOS, so the reported age range encompasses ages after 30; the paper does not identify 30 as a threshold. (LLM, conf=0.93)

  cites [334] Pani, 2008, Effect of aging on A1c levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004, Diabetes Care source
• ?Not checked — no full text of the sourcecites [335] Ziemer, 2010, Glucose-independent, black-white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies, Ann Intern Med source

In the paper

“Few published studies have convincingly demonstrated a relationship between glycated protein levels and the chronic complications of diabetes (317).”

What the sources say

• Partly supported

  The Introduction (page unavailable) cites studies associating fructosamine or glycated albumin with long-term complications, and the Discussion reports an association between glycated albumin and microvascular complications. The paper does not say that few published studies have convincingly demonstrated such relationships; it also describes the HbA1c–complications relationship as well established. (LLM, conf=0.78)

  cites [317] Nathan, 2014, Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study, Diabetes sourceExperimental — accuracy not yet measured

In the paper

“Several technical advantages of HbA 1c testing compared with glucose testing, such as its preanalytic stability and decreased biological variability (318), also played a role.”

What the sources say

• Supported

  The A1C Measurement section lists very little biological variability and sample stability as advantages of A1C for diagnosing diabetes. The Perspective section says the absence of sample lability, together with other advantages in that table, helped lead organizations to recommend A1C for screening and diagnosis; it contrasts these features with glucose testing’s variability and lack of sample stability. (LLM, conf=0.94)

  cites [318] Sacks, 2011, A1c versus glucose testing: a comparison, Diabetes Care source

In the paper

“A meta-analysis published in 2017 revealed continuing problems with the accuracy of POCT devices (324).”

What the sources say

• Supported

  The Results report large variability in bias for most point-of-care HbA1c devices, with statistically significant mean bias for several devices. The Clinical implications section says these biases and large standard deviations may affect treatment decisions compared with laboratory results. These findings support the claim that the 2017 meta-analysis identified continuing accuracy problems. (LLM, conf=0.93)

  cites [324] Hirst, 2017, Performance of point-of-care HbA1c test devices: implications for use in clinical practice—a systematic review and meta-analysis, Clin Chem Lab Med source

In the paper

“Moreover, the introduction of CGM devices that alarm with low blood glucose concentrations and semiautomated pumps that suspend insulin infusion as glucose concentrations decrease have facilitated achieving target HbA 1c levels with less risk for hypoglycemia (332).”

What the sources say

• Partly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [332] Brown, 2019, Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured

In the paper

“Sample stability is assay methodspecific (351,352).”

What the sources say

• Supported

  The Results report different stability periods for the G7, G8, and ultra2 assay methods under the same storage conditions. The Discussion likewise compares stability across methods, supporting the claim that sample stability is assay-method-specific. (LLM, conf=0.94)

  cites [351] Rohlfing, 2012, Effects of whole blood storage on hemoglobin a1c measurements with five current assay methods, Diabetes Technol Ther source
• ?Not checked — no full text of the sourcecites [352] Little, 2007, Effects of sample storage conditions on glycated hemoglobin measurement: evaluation of five different high performance liquid chromatography methods, Diabetes Technol Ther source

In the paper

“Any condition that shortens RBC survival or decreases mean RBC age (e.g., recovery from acute blood loss, hemolytic anemia) falsely lowers HbA 1c test results, compared with mean glycemia, regardless of the assay method (295).”

What the sources say

• Supported

  The Chemistry and terminology section (page not available) states that shortened erythrocyte survival or reduced mean erythrocyte age falsely lowers glycated hemoglobin (GHb) results regardless of assay method. The paper also describes GHb as an index of mean glycemia. It does not name the parenthetical examples, but they illustrate the stated condition. (LLM, conf=0.92)

  cites [295] Goldstein, 2004, Tests of glycemia in diabetes, Diabetes Care source

In the paper

“Several hemoglobin variants (e.g., hemoglobins S, C, D, and E) and chemically modified derivatives of hemoglobin interfere with some assay methods (independent of any effects due to shortened RBC survival) (348-350) (for a review, see reference 347).”

What the sources say

• Partly supported

  The Conclusions (section labeled “Schnedl and Associates”; page not provided) state that hemoglobin variants interfere with HbA1c methods, and the paper reports method-dependent results for Hb S and Hb D. Our copy does not establish interference from chemically modified hemoglobin derivatives or the cited examples Hb C and Hb E. (LLM, conf=0.87)

  cites [348] Schnedl, 2000, Evaluation of Hb1c determination methods in patients with hemoglobinopathies, Diabetes Care sourceExperimental — accuracy not yet measured
• Partly supported

  The Introduction identifies method-specific interference from hemoglobin S, C, D, and E traits, and the Results report clinically significant interference for some assays. The paper does not address interference from chemically modified hemoglobin derivatives. Page numbers are not available in our copy. (LLM, conf=0.88)

  cites [349] Rohlfing, 2021, Evaluation of interference from hemoglobin C, D, E and S traits on measurements of hemoglobin A1c by fifteen methods, Clin Chim Acta sourceExperimental — accuracy not yet measured
• Partly supported

  The Abstract and Conclusions report that hemoglobin variants can interfere with some HbA1c assay methods, including analytical interference distinct from effects of shortened red-cell survival. Our copy does not report that chemically modified hemoglobin derivatives interfere with those methods; they appear only in a cited reference’s title. Page numbers are unavailable in our copy. (LLM, conf=0.86)

  cites [350] Little, 2015, Effects of 49 different rare HhHb variants on HbA1c measurement in eight methods, J Diabetes Sci Technol sourceExperimental — accuracy not yet measured

In the paper

“The accuracy of such collection methods has been validated in several large research cohorts (353,354).”

What the sources say

• ?Not checked — no full text of the sourcecites [353] Beck, 2021, An evaluation of two capillary sample collection kits for laboratory measurement of HbA1c, Diabetes Technol Ther source
• Supported

  The Study design section says that both the GRADE and EDIC studies evaluated the accuracy of HbA1c results from self-collected capillary blood against same-day venous samples. The Discussion reports that the results were comparable and highly correlated in both studies. The validation is specifically for capillary collection used to measure HbA1c. (LLM, conf=0.90)

  cites [354] Nathan, 2021, Comparison of central laboratory HbA1c measurements obtained from a capillary collection versus a standard venous whole blood collection in the GRADE and EDIC studies, PLoS One source

In the paper

“An analysis of 11,092 adults showed that Black individuals had mean HbA 1c values 0.4% higher than White individuals (336).”

What the sources say

• Supported

  The Methods report glycated hemoglobin measurements in 11,092 Black or White adults. The Results report mean values of 5.8% for Black participants and 5.4% for White participants, a difference of 0.4 percentage points. Page numbers were not provided in our copy. (LLM, conf=0.95)

  cites [336] Selvin, 2010, Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults, N Engl J Med source

In the paper

“Since initiation of the NGSP in 1996, the College of American Pathologists proficiency testing survey has documented a steady improvement in comparability of GHb values among laboratories, both within method and between method (357,358,361).”

What the sources say

• Supported

  The Introduction states that the NGSP was established in 1996 and that proficiency-testing data showed reduced HbA1c variability, with further improvement over the years. The Status of HbA1c Measurement section explicitly attributes improved comparability within and among assay methods to CAP GH survey data; the Summary also reports reduced variability among laboratories. (LLM, conf=0.94)

  cites [357] Little, 2019, The national glycohemoglobin standardization program: over 20 years of improving hemoglobin A1c measurement, Clin Chem source
• ?Not checked — no full text of the sourcecites [358] Little, 2001, The national glycohemoglobin standardization program: a five-year progress report, Clin Chem
• ?Not checked — no full text of the sourcecites [361] Little, 2011, Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care, Clin Chem source

In the paper

“However, race did not modify the association between the HbA 1c concentration and adverse cardiovascular outcomes or death (336).”

What the sources say

• Supported

  The Discussion explicitly states that race did not modify the associations between glycated hemoglobin and cardiovascular outcomes or death in the study population. The Results likewise report no significant race interaction for coronary heart disease, ischemic stroke, or death from any cause. (LLM, conf=0.95)

  cites [336] Selvin, 2010, Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults, N Engl J Med source

In the paper

“Several studies have suggested a relatively higher HbA 1c in Black and Hispanic populations than in White populations at the same level of glycemia, although glucose levels have not always been measured comprehensively to be confident that they capture true average glycemia (335,338,339).”

What the sources say

• ?Not checked — no full text of the sourcecites [335] Ziemer, 2010, Glucose-independent, black-white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies, Ann Intern Med source
• Supported

  The Results report higher adjusted A1C in Black and Hispanic participants than in White participants after accounting for fasting glucose and glucose AUC. The Conclusions state that these differences persisted after adjustment for post–glucose load measures, while acknowledging that the measured glucose levels may not robustly reflect the 24-hour glucose profile. (LLM, conf=0.92)

  cites [338] Herman, 2007, Differences in A1c by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program, Diabetes Care source
• Partly supported

  The Statistical analysis (p. 3) reports higher HbA1c in both non-Hispanic Black and Mexican-American youths than in White youths, but its fasting-glucose-adjusted result establishes the difference only for Black youths. The discussion (p. 4) cautions that the differences could reflect higher average glycemia, so the paper does not establish higher HbA1c for both groups at the same true average glycemia. (LLM, conf=0.86)

  cites [339] Saaddine, 2002, Distribution of HbA(1c) levels for children and young adults in the U.S.: Third National Health and Nutrition Examination Survey, Diabetes Care sourceExperimental — accuracy not yet measured

In the paper

“The consistency of glycemic measurements within races and the similar relationship of each glycemic measurement with complications in Black compared with White populations suggests that higher HbA 1c measurements in Black populations reflects, at least in part, higher glycemic exposure and not just a difference in the relationship between mean glycemia and HbA 1c levels.”

What the sources say

• Supported

  Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  cites [340] Parrinello, 2016, Racial differences in and prognostic value of biomarkers of hyperglycemia, Diabetes Care source

In the paper

“There is some evidence to suggest that immediate feedback of HbA 1c test results to patients at the time of the clinic visit improves long-term glycemic control (369,370).”

What the sources say

• ?Not checked — no full text of the sourcecites [369] Cagliero, 1999, Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients, Diabetes Care source
• Partly supported

  The Secondary outcomes section reports that point-of-care A1C testing increased the proportion reaching the A1C target in a subgroup with baseline A1C above 10%. But the discussion says immediate results generally added no glycemic benefit beyond active insulin titration. The study measured outcomes over six months, so it does not establish a general improvement in long-term control. (LLM, conf=0.86)

  cites [370] Kennedy, 2006, Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the glycemic optimization with algorithms and labs at point of care (GOAL A1c) trial, Diabetes Care sourceExperimental — accuracy not yet measured

In the paper

“Thus, HLA-DR-DQ typing can be used only to increase or decrease the probability of type 1 diabetes and cannot be recommended for routine clinical diagnosis or classification (388).”

What the sources say

• Partly supported

  The Introduction (page not provided) describes HLA DR-DQ haplotypes as important factors that increase or decrease type 1 diabetes risk, supporting the probability-related part of the claim. The paper does not say that HLA-DR-DQ typing is limited to that use or recommend against its routine use for clinical diagnosis or classification. (LLM, conf=0.84)

  cites [388] Sharp, 2019, Development and standardization of an improved type 1 diabetes genetic risk score for use in newborn screening and incident diagnosis, Diabetes Care sourceExperimental — accuracy not yet measured

In the paper

“Capillary blood sample kits have been used in research studies and shown to perform well compared with venous whole-blood samples when assayed with a high-performance chromatography method (353,354).”

What the sources say

• ?Not checked — no full text of the sourcecites [353] Beck, 2021, An evaluation of two capillary sample collection kits for laboratory measurement of HbA1c, Diabetes Technol Ther source
• Supported

  The Introduction says the capillary samples were assayed by the same high-performance liquid chromatography method as venous whole-blood samples. The Abstract Conclusions say the HbA1c results compared well, and the Discussion reports that the kits were used in the GRADE and EDIC studies. (LLM, conf=0.94)

  cites [354] Nathan, 2021, Comparison of central laboratory HbA1c measurements obtained from a capillary collection versus a standard venous whole blood collection in the GRADE and EDIC studies, PLoS One source

In the paper

“Non-HLA genetic factors include the genes for insulin (INS), PTPN22, CTLA-4, and several others (386,387).”

What the sources say

• Supported

  The paper’s Abstract explicitly identifies INS, CTLA4, PTPN22, and IL2RA as non-HLA type 1 diabetes risk loci. This supports the cited examples and the reference to additional genes. (LLM, conf=0.95)

  cites [386] Barrett, 2009, Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes, Nat Genet source
• ?Not checked — no full text of the sourcecites [387] Concannon, 2009, Genetics of type 1A diabetes, N Engl J Med source

In the paper

“The equation generated by the ADAG study is generally considered the most reliable one to date (341).”

What the sources say

• Partly supported

  The Conclusions describe the ADAG equation as based on more complete glucose measurements than earlier studies and report less scatter than the widely used DCCT equation. They do not establish that it is generally considered the most reliable equation to date. (LLM, conf=0.82)

  cites [341] Nathan, 2008, Translating the A1c assay into estimated average glucose values, Diabetes Care sourceExperimental — accuracy not yet measured

In the paper

“Several studies have demonstrated a close mathematical relationship between the HbA 1c concentration and mean glycemia that should allow expression of HbA 1c as an eAG (341,373,374).”

What the sources say

• Supported

  The Abstract conclusions say several studies supported an association between A1C and average glucose, while noting limitations in older studies. The paper's Conclusions report a strong linear relationship in the ADAG study and say it justifies translating measured A1C into estimated average glucose for most patients with type 1 or type 2 diabetes. (LLM, conf=0.93)

  cites [341] Nathan, 2008, Translating the A1c assay into estimated average glucose values, Diabetes Care source
• ?Not checked — no full text of the sourcecites [373] Murata, 2004, Contributions of weekly mean blood glucose values to hemoglobin A1c in insulin-treated type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES), Am J Med Sci source
• Supported

  The Discussion states that the mathematical relationship established in this study should allow HbA1c to be expressed as an equivalent mean glucose level. The Conclusions also report a close correlation and say translation to average glucose is feasible, while noting that a larger, more diverse study should confirm the relationship before routine use. (LLM, conf=0.92)

  cites [374] Nathan, 2007, Relationship between glycated haemoglobin levels and mean glucose levels over time, Diabetologia source

In the paper

“Genome-wide association studies have confirmed a number of non-HLA genetic factors that increase the risk of a first appearing b-cell autoantibody or type 1 diabetes, both in first degree relatives of individuals with type 1 diabetes and in the general population (386,387,404,405).”

What the sources say

• Partly supported

  The Abstract (page not supplied) reports associations between multiple non-HLA loci and type 1 diabetes, tested in case-control samples and affected sib-pair families. It does not report risk of a first-appearing beta-cell autoantibody, and the affected sib-pair families do not establish the claimed finding in first-degree relatives generally. (LLM, conf=0.88)

  cites [386] Barrett, 2009, Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes, Nat Genet sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [387] Concannon, 2009, Genetics of type 1A diabetes, N Engl J Med source
• Partly supported

  The Type 1 diabetes (T1D) section reports associations between several non-HLA regions and T1D susceptibility, including findings confirmed in independent populations. It does not report risk of a first-appearing beta-cell autoantibody or assess these associations specifically in first-degree relatives of people with T1D. (LLM, conf=0.88)

  cites [404] Wellcome Trust Case Control Consortium, 2007, Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls, Nature sourceExperimental — accuracy not yet measured
• Partly supported

  The Abstract reports confirmed associations between non-HLA chromosome regions and type 1 diabetes in independent cases and controls and in parent–child trios. It does not report whether these factors increase the risk of a first-appearing β-cell autoantibody, so that part of the citing sentence is unsupported by this paper. (LLM, conf=0.85)

  cites [405] Todd, 2007, Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes, Nat Genet sourceExperimental — accuracy not yet measured

In the paper

“For example, infants with neonatal diabetes due to a mutation in the KCNJ11 (Kir6.2) gene may be treated with a sulfonylurea rather than with insulin (382,384,398).”

What the sources say

• Supported

  The Results section reports that 11 of 14 patients with KCNJ11 mutations were successfully transferred from insulin to glyburide, a sulfonylurea. The Conclusions likewise identify sulfonylurea therapy as a treatment option for neonatal diabetes with KCNJ11 mutations. (LLM, conf=0.94)

  cites [382] Støy, 2008, Diagnosis and treatment of neonatal diabetes: a United States experience, Pediatr Diabetes source
• ?Could not verify

  The Introduction and Results discuss sulphonylurea treatment for HNF1A and HNF4A MODY, not KCNJ11-related neonatal diabetes. Searches for KCNJ11/Kir6.2 and neonatal diabetes found no passage in our copy addressing whether affected infants can use a sulfonylurea instead of insulin. (LLM, conf=0.77)

  cites [384] Carlsson, 2020, Absence of islet autoantibodies and modestly raised glucose values at diabetes diagnosis should lead to testing for MODY: lessons from a 5-year pediatric Swedish National Cohort Study, Diabetes Care sourceExperimental — accuracy not yet measured
• Supported

  The Sulphonylurea therapy section (p. 10) says that patients with neonatal diabetes caused by mutations in Kir6.2 or SUR1, previously treated with insulin injections, can instead be managed with oral sulphonylureas. It also notes that transfer is not successful for every patient (p. 11), consistent with the claim’s “may be treated” wording. (LLM, conf=0.94)

  cites [398] Pipatpolkai, 2020, New insights into KATP channel gene mutations and neonatal diabetes mellitus, Nat Rev Endocrinol source

In the paper

“Autoantibody markers are usually present in 85% to 90% of individuals with type 1 diabetes when fasting hyperglycemia is initially detected (2).”

What the sources say

• Partly supported

  The Diagnosis section says that stage 1 type 1 diabetes is defined by two or more autoimmune markers, supporting their role in the disease. Our copy does not give an 85%–90% prevalence or tie that figure to the initial detection of fasting hyperglycemia; searches for those terms found no matching passage. Page numbers were not provided. (LLM, conf=0.82)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care sourceExperimental — accuracy not yet measured

In the paper

“A genetic risk score may be used at birth to identify children with a particularly high genetic risk of development of islet autoimmunity or type 1 diabetes (388,390,392).”

What the sources say

• Supported

  The Abstract (Results; no page provided) reports that T1D GRS2 improved prediction of type 1 diabetes in simulated newborn screening. The Conclusions (no page provided) say it was most predictive in very early life and may help identify children at risk of early-onset T1D. This supports the claim’s hedged statement about identifying children at high genetic risk of type 1 diabetes at birth. (LLM, conf=0.90)

  cites [388] Sharp, 2019, Development and standardization of an improved type 1 diabetes genetic risk score for use in newborn screening and incident diagnosis, Diabetes Care source
• Supported

  The Results describe selecting newborn infants with high genetic risk using GRS2. Extended Data Fig. 2 evaluates genetic risk scores for predicting type 1 diabetes from birth. The claim’s cautious wording is consistent with those passages; no page numbers are available in our copy. (LLM, conf=0.91)

  cites [390] Ferrat, 2020, A combined risk score enhances prediction of type 1 diabetes among susceptible children, Nat Med source
• Supported

  The Discussion reports that a genetic score identified a small group of newborns with greater than 10% risk of developing multiple islet autoantibodies by age six. It also states that the score stratified risk of clinical type 1 diabetes. (LLM, conf=0.94)

  cites [392] Bonifacio, 2018, Genetic scores to stratify risk of developing multiple islet autoantibodies and type 1 diabetes: a prospective study in children, PLoS Med source

In the paper

“The risk of type 1 diabetes in the general population may be determined by HLA-DQ typing, which contribute as much as 50% of familial susceptibility (400).”

What the sources say

• Partly supported

  The HLA region section says the HLA region accounts for approximately 50% of familial aggregation of type 1 diabetes, with the strongest association at HLA-DR and HLA-DQ. The Genetic scores section discusses HLA-DR/DQ genotyping for risk prediction in children from the general population. The paper does not assign the full 50% contribution to HLA-DQ alone or say that HLA-DQ typing by itself determines risk. (LLM, conf=0.88)

  cites [400] Redondo, 2018, Genetics of type 1 diabetes, Pediatr Diabetes sourceExperimental — accuracy not yet measured

In the paper

“In those individuals who are islet autoantibody positive, HLA-DR-DQ genotyping or an analysis of Genetic Risk Score (388,392) will help define the risk of type 1 diabetes.”

What the sources say

• Partly supported

  The Introduction identifies HLA-DR-DQ as a major contributor to type 1 diabetes risk and says genetic risk scores improve risk discrimination. The Conclusions report that a model combining autoantibody data, a genetic risk score, age, and a metabolic score predicted progression in at-risk relatives. The paper does not establish that HLA-DR-DQ genotyping or a genetic risk score alone defines risk specifically among autoantibody-positive individuals. (LLM, conf=0.82)

  cites [388] Sharp, 2019, Development and standardization of an improved type 1 diabetes genetic risk score for use in newborn screening and incident diagnosis, Diabetes Care sourceExperimental — accuracy not yet measured
• Partly supported

  The Discussion (page unavailable) reports that genetic scores stratified the risk of developing islet autoantibodies and clinical type 1 diabetes in children with high-risk HLA genotypes. But the study assessed risk from infancy, before autoantibody development; it does not establish that HLA genotyping or a genetic risk score defines diabetes risk specifically among people who are already islet-autoantibody positive. (LLM, conf=0.86)

  cites [392] Bonifacio, 2018, Genetic scores to stratify risk of developing multiple islet autoantibodies and type 1 diabetes: a prospective study in children, PLoS Med sourceExperimental — accuracy not yet measured

In the paper

“The performance of GADA and IA-2A assays is improving, as demonstrated by the Islet Autoantibody Standardization Program (440,442).”

What the sources say

• ?Not checked — no full text of the sourcecites [440] Bonifacio, 2010, Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for National Institute of Diabetes and Digestive and Kidney Diseases consortia, J Clin Endocrinol Metab source
• Partly supported

  The Abstract Conclusions and Discussion report high-performing GADA assays, including nonradioactive formats that performed as well as or better than the previous gold-standard format. But this 2018 comparison does not establish a trend of improvement over time, and it evaluates GADA assays, not IA-2A assays. No page numbers are provided in our copy. (LLM, conf=0.85)

  cites [442] Lampasona, 2019, Islet Autoantibody Standardization Program 2018 workshop: interlaboratory comparison of glutamic acid decarboxylase autoantibody assay performance, Clin Chem sourceExperimental — accuracy not yet measured

In the paper

“Because of the low prevalence of type 1 diabetes (approximately 0.3% in the general population), the positive predictive value of a single islet autoantibody is low (408).”

What the sources say

• Partly supported

  The Results report a 12.7% risk of diabetes by age 15 in children with one islet autoantibody, versus 61.6% with two, supporting the point that a single antibody is less predictive. The paper does not give a 0.3% general-population prevalence or attribute the lower predictive value to that prevalence. The Discussion also cautions that its genetically susceptible cohort may not represent the general population (page numbers unavailable). (LLM, conf=0.86)

  cites [408] Ziegler, 2013, Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children, JAMA sourceExperimental — accuracy not yet measured

In the paper

“The CD3 monoclonal antibody teplizumab has been shown to delay progression to type 1 diabetes in high-risk individuals (429).”

What the sources say

• Supported

  The Methods identify teplizumab as an anti-CD3 monoclonal antibody and describe a trial in relatives at high risk of clinical type 1 diabetes. The Results (Efficacy) report that treatment delayed diagnosis compared with placebo; the Discussion specifies that participants were high-risk, nondiabetic relatives. (LLM, conf=0.95)

  cites [429] Herold, 2019, An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes, N Engl J Med source

In the paper

“In islet cell or pancreas transplantation, the presence or absence of islet autoantibodies may indicate whether a subsequent failure of the transplanted islets is due to recurrent autoimmune disease or to rejection (431).”

What the sources say

• Partly supported

  The conclusion (RESEARCH DESIGN AND METHODS > B A; page unavailable) says that rising islet autoantibodies after pancreas transplantation may identify graft failures caused by recurrent autoimmunity. The paper does not establish that absent antibodies indicate rejection, and its own study concerns pancreas rather than islet-cell transplants. (LLM, conf=0.87)

  cites [431] Braghi, 2000, Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes, Diabetes sourceExperimental — accuracy not yet measured

In the paper

“approximately 10% of individuals presenting with new-onset diabetes express only a single autoantibody (445).”

What the sources say

• Partly supported

  The Results section ('ICA positivity in children enrolled in the Better Diabetes Diagnosis Study'; page unavailable) reports a single autoantibody—ICA—in 17 of 229 children with type 1 diabetes who had tested negative for the other autoantibodies, or about 7%. That is a selected subgroup, not approximately 10% of all individuals presenting with new-onset diabetes; the paper does not give the claimed overall prevalence of exactly one autoantibody. (LLM, conf=0.86)

  cites [445] Andersson, 2014, Islet cell antibodies (ICA) identify autoimmunity in children with new onset diabetes mellitus negative for other islet cell antibodies, Pediatr Diabetes sourceExperimental — accuracy not yet measured

In the paper

“At diagnosis of diabetes in children, absence of all four islet autoantibodies and modest hyperglycemia (HbA 1c <7.5% [58 mmol/mol]) proved useful for the detection of MODY (384).”

What the sources say

• Supported

  The Conclusions state that, at pediatric diabetes diagnosis, negativity for four islet autoantibodies and HbA1c below 7.5% can guide MODY testing. The Abstract Results report that applying both criteria identified 36 of 46 patients with MODY in the tested group. Page numbers are not provided in our copy. (LLM, conf=0.95)

  cites [384] Carlsson, 2020, Absence of islet autoantibodies and modestly raised glucose values at diabetes diagnosis should lead to testing for MODY: lessons from a 5-year pediatric Swedish National Cohort Study, Diabetes Care source

In the paper

“However, high-risk individuals identified within such protocols are less likely to present in DKA (430).”

What the sources say

• Supported

  The Introduction says children participating in prospective studies such as TEDDY have less DKA at diagnosis. The Results report no DKA among 43 TEDDY children, compared with 14% of 43 community controls. (LLM, conf=0.92)

  cites [430] Steck, 2017, Residual beta-cell function in diabetes children followed and diagnosed in the TEDDY study compared to community controls, Pediatr Diabetes source

In the paper

“Only about 15% of individuals with newly diagnosed type 1 diabetes have a first-degree relative with the disease (420).”

What the sources say

• ?Could not verify

  The Abstract reports incidence trends and predicted numbers of new childhood type 1 diabetes cases in Europe, not family history. Searches for “first-degree,” “family history,” and “15%” found no passage in our copy stating what proportion of newly diagnosed people have an affected first-degree relative. (LLM, conf=0.77)

  cites [420] Patterson, 2009, Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study, Lancet sourceExperimental — accuracy not yet measured

In the paper

“they will be at moderately increased risk of cardiovascular mortality, with severity of chronic kidney disease (CKD) acting as a risk multiplier (458,459).”

What the sources say

• Partly supported

  The Outcomes According to the Estimated GFR section reports that cardiovascular-event risk rises as estimated GFR falls, supporting the CKD-severity part of the citing sentence. It measures death from any cause separately, not cardiovascular mortality, and does not establish the stated risk specifically for people over 75 or with life expectancy under 20 years. The Statistical Analysis section uses age categories but does not supply those claimed subgroup findings; page numbers are unavailable in our copy. (LLM, conf=0.87)

  cites [458] Go, 2004, Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization, N Engl J Med sourceExperimental — accuracy not yet measured
• Partly supported

  The Discussion reports that participants with CKD had a higher risk of cardiovascular events than those without CKD. It does not establish cardiovascular mortality risk specifically, quantify it as moderate, or show that risk rises with CKD severity. The Results table lists participants aged ≥75 but does not link that age group—or life expectancy under 20 years—to cardiovascular mortality. (LLM, conf=0.84)

  cites [459] Beddhu, 2021, Chronic kidney disease, atherosclerotic plaque characteristics on carotid magnetic resonance imaging, and cardiovascular outcomes, BMC Nephrol sourceExperimental — accuracy not yet measured

In the paper

“Published studies have also demonstrated that it is costeffective to screen all people with diabetes and/or kidney disease for albuminuria (461,462).”

What the sources say

• ?Not checked — no full text of the sourcecites [461] Lepore, 2002, Cost-effectiveness of two screening programs for microalbuminuria in type 2 diabetes, Diabetes Care source
• Partly supported

  The Cost of microalbuminuria diagnosis section compares per-patient costs of three screening tests in patients with diabetes, and the Discussion identifies the lowest-cost test. It does not establish that screening all people with diabetes is cost-effective, or assess screening people with kidney disease generally. (LLM, conf=0.87)

  cites [462] Incerti, 2005, Evaluation of tests for microalbuminuria screening in patients with diabetes, Nephrol Dial Transplant sourceExperimental — accuracy not yet measured

In the paper

“there is now evidence that the anti-CD3 monoclonal antibody teplizumab delays progression to type 1 diabetes in high-risk individuals (429).”

What the sources say

• Supported

  The Methods identify teplizumab as an anti-CD3 monoclonal antibody and the participants as relatives at high risk of clinical type 1 diabetes. The Results report that a single course delayed diagnosis compared with placebo; the Discussion describes a median delay of two years. (LLM, conf=0.94)

  cites [429] Herold, 2019, An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes, N Engl J Med source

In the paper

“The Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) outcome trial (460) demonstrates a significant relationship between reduction in moderately increased albuminuria and reduction in cardiovascular risk.”

What the sources say

• Partly supported

  The Results report a significant reduction in cardiovascular events with finerenone, and Secondary and Exploratory Outcomes report a greater reduction in urinary albumin-to-creatinine ratio than with placebo. The paper does not demonstrate a significant relationship between the *reduction in albuminuria* and the *reduction in cardiovascular risk*; it reports them as separate outcomes. The trial also included patients with severely, as well as moderately, elevated albuminuria. (LLM, conf=0.87)

  cites [460] Pitt, 2021, Cardiovascular events with finerenone in kidney disease and type 2 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured

In the paper

“SGLT2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, also reduce albuminuria in clinical trials of advanced diabetic kidney disease (471-473).”

What the sources say

• Partly supported

  The Effect on Intermediate Outcomes section reports that urinary albumin-to-creatinine ratio was 31% lower with canagliflozin, an SGLT2 inhibitor, than with placebo during follow-up. The Methods describe patients with type 2 diabetes and albuminuric chronic kidney disease, but the paper does not report a finerenone trial; it also says patients with very advanced kidney disease (estimated GFR below 30) were excluded. (LLM, conf=0.88)

  cites [471] Perkovic, 2019, Canagliflozin and renal outcomes in type 2 diabetes and nephropathy, N Engl J Med sourceExperimental — accuracy not yet measured
• Partly supported

  The Participants and Discussion sections describe a clinical trial of dapagliflozin, an SGLT2 inhibitor, in people with chronic kidney disease, including those with type 2 diabetes. The reported benefit concerns kidney and cardiovascular outcomes; the paper does not report that dapagliflozin reduced albuminuria, and it does not address finerenone. (LLM, conf=0.81)

  cites [472] Heerspink, 2020, Dapagliflozin in patients with chronic kidney disease, N Engl J Med sourceExperimental — accuracy not yet measured
• Supported

  This finerenone trial supports the finerenone part of the multi-citation sentence. In Other Secondary and Exploratory Outcomes, it reports a lower urinary albumin-to-creatinine ratio with finerenone than with placebo, maintained over time; the Discussion describes the participants as having type 2 diabetes and advanced CKD. The paper compares kidney outcomes with an SGLT2-inhibitor trial but does not establish the SGLT2 albuminuria claim. (LLM, conf=0.92)

  cites [473] Bakris, 2020, Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes, N Engl J Med source

In the paper

“with severity of chronic kidney disease (CKD) acting as a risk multiplier (458,459).”

What the sources say

• Partly supported

  The Abstract reports a graded association between lower estimated GFR and higher risks of death and cardiovascular events. The outcomes section specifies that death was measured from any cause and cardiovascular events were defined by hospitalization, so these passages do not establish a graded increase in cardiovascular mortality specifically. The study reports an association, not a causal multiplier. (LLM, conf=0.86)

  cites [458] Go, 2004, Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization, N Engl J Med sourceExperimental — accuracy not yet measured
• Partly supported

  The Results report that CKD was associated with a higher risk of cardiovascular events (HR 3.35), and the Methods define those events as a composite that includes cardiovascular death. The study compares CKD with non-CKD participants; it does not establish that increasing CKD severity multiplies the risk of cardiovascular mortality specifically. (LLM, conf=0.88)

  cites [459] Beddhu, 2021, Chronic kidney disease, atherosclerotic plaque characteristics on carotid magnetic resonance imaging, and cardiovascular outcomes, BMC Nephrol sourceExperimental — accuracy not yet measured

In the paper

“reinforcing the notion that albuminuria is a continuous variable for cardiovascular risk (466-468).”

What the sources say

• Partly supported

  The Results section concludes that microalbuminuria predicts cardiovascular risk in people with type 1 diabetes. The WHO definition section uses an albumin-excretion cutoff, however, and the paper does not establish that cardiovascular risk varies continuously with albuminuria levels or extend its finding beyond this population. Page numbers are unavailable in our copy. (LLM, conf=0.85)

  cites [466] Pambianco, 2007, The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience, Diabetes Care sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [467] Rachmani, 2000, Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus: lessons from an 8-year follow-up study of 599 patients, Diabetes Res Clin Pract source
• ?Not checked — no full text of the sourcecites [468] Wachtell, 2003, Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study, Ann Intern Med source

In the paper

“The uACR may also be useful in determining the rate of progression of disease and thus support planning for care of end-stage renal disease using the Kidney Failure Risk Equation (474).”

What the sources say

• Supported

  The Introduction identifies urinary ACR as an input to the four-variable KFRE, which predicts progression from CKD to kidney failure. The Discussion reports that the equation predicts kidney-failure risk over two and five years and can inform dialysis-access and transplant planning. (LLM, conf=0.90)

  cites [474] Tangri, 2016, Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis, JAMA source

In the paper

“While older individuals (age >75 years) or with life expectancy <20 years may not be at increased risk of kidney failure requiring replacement therapy during their lifetimes”

What the sources say

• ?Could not verify

  The Outcomes According to the Estimated GFR section reports how many participants began dialysis or underwent transplantation during a median 2.84-year follow-up. Neither that section nor the other passages located by searches for age over 75 and life expectancy under 20 years assesses whether those groups are at increased risk of kidney failure requiring replacement therapy during their lifetimes. (LLM, conf=0.74)

  cites [458] Go, 2004, Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization, N Engl J Med sourceExperimental — accuracy not yet measured
• ?Could not verify

  The Results report participants’ ages, including the proportion aged 75 or older, while the Background and Discussion address cardiovascular events and carotid plaque in CKD. Searches for kidney failure requiring replacement therapy and for the stated age and life-expectancy thresholds found no passage assessing lifetime risk of kidney failure. (LLM, conf=0.74)

  cites [459] Beddhu, 2021, Chronic kidney disease, atherosclerotic plaque characteristics on carotid magnetic resonance imaging, and cardiovascular outcomes, BMC Nephrol sourceExperimental — accuracy not yet measured

In the paper

“Most longitudinal cohort studies report significant increases in the prevalence of moderately increased albuminuria only after type 1 diabetes has been present for 5 years (456,457).”

What the sources say

• Supported

  The section on when to begin kidney-disease screening in type 1 diabetes states that most longitudinal cohorts report significant increases in microalbuminuria prevalence only after five years’ duration. Microalbuminuria corresponds to moderately increased albuminuria; the section separately notes an exception from a cross-sectional study. (LLM, conf=0.95)

  cites [456] KDOQI, 2007, KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease, Am J Kidney Dis source
• ?Not checked — no full text of the sourcecites [457] Vassalotti, 2007, Testing for chronic kidney disease: a position statement from the National Kidney Foundation, Am J Kidney Dis source

In the paper

“Moreover, cardiovascular risk may extend below the lower limit of 30 mg/day (463-465)”

What the sources say

• ?Not checked — no full text of the sourcecites [463] Klausen, 2006, Very low level of microalbuminuria is associated with increased risk of death in subjects with cardiovascular or cerebrovascular diseases, J Intern Med source
• ?Not checked — no full text of the sourcecites [464] Klausen, 2005, New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death, Hypertension source
• Supported

  The Discussion says the relationship between urinary albumin excretion and cardiovascular risk factors appears graded, and that levels below conventional microalbuminuria cutoffs have prognostic value in hypertensive patients. The study also found that a lower albumin-to-creatinine ratio threshold improved cardiovascular risk assessment. Our copy reports these thresholds in mg/g rather than mg/day, but supports the claim’s qualified point that risk may extend below the conventional lower limit. (LLM, conf=0.91)

  cites [465] Ratto, 2006, Microalbuminuria and cardiovascular risk assessment in primary hypertension: should threshold levels be revised?, Am J Hypertens source

In the paper

“Mean biases were large and ranged from À35% to 34% at 15 mg/L.”

What the sources say

• Supported

  The Results state that mean bias across the quantitative urine albumin measurement procedures ranged from −35% to 34% for concentrations near 15 mg/L (Table 2). The Abstract also gives that range at 15 mg/L. (LLM, conf=0.95)

  cites [498] Bachmann, 2014, State of the art for measurement of urine albumin: comparison of routine measurement procedures to isotope dilution tandem mass spectrometry, Clin Chem source

In the paper

“In multiple epidemiological studies, moderately increased albuminuria is an independent risk marker for cardiovascular death (481-483).”

What the sources say

• ?Not checked — no full text of the sourcecites [481] Levey, 2011, The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report, Kidney Int source
• Partly supported

  The Comment section (page unavailable) describes urinary albumin excretion as a well-known risk marker and says this study found it independently predicted death and a first major cardiovascular event. The Mortality and Cardiovascular Events sections report all-cause death and a composite cardiovascular outcome, respectively; they do not establish an independent association specifically with cardiovascular death. The passages also do not identify the studied levels as moderately increased albuminuria. (LLM, conf=0.84)

  cites [482] Kistorp, 2005, N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults, JAMA sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [483] Yuyun, 2004, Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study, Int J Epidemiol source

In the paper

“Others have validated the reliability of a first morning void sample (462,492, 493).”

What the sources say

• Partly supported

  The Discussion reports that albumin measurements from first-morning urine correlate more closely with 24-hour protein excretion than measurements from random spot samples. However, the study itself tested random spot samples, not first-morning voids, so it reports evidence for their reliability rather than independently validating them. (LLM, conf=0.84)

  cites [462] Incerti, 2005, Evaluation of tests for microalbuminuria screening in patients with diabetes, Nephrol Dial Transplant sourceExperimental — accuracy not yet measured
• ?Not checked — no full text of the sourcecites [492] Gansevoort, 2005, The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population, Kidney Int Suppl source
• ?Not checked — no full text of the sourcecites [493] Meinhardt, 2003, Microalbuminuria in diabetes mellitus: efficacy of a new screening method in comparison with timed overnight urine collection, J Diabetes Complications source

In the paper

“Moreover, approximately 20% of people with diabetes progress to end-stage kidney disease without an increase in moderately increased albuminuria (488).”

What the sources say

• ?Could not verify

  The introduction discusses ESRD risk and persistent microalbuminuria, while the Discussion describes kidney injury that can precede albuminuria. Neither section reports that approximately 20% of people with diabetes reach ESRD without an increase in albuminuria. Searches for that percentage and for progression to ESRD without microalbuminuria found no supporting passage. (LLM, conf=0.75)

  cites [488] Steinke, 2005, The early natural history of nephropathy in type 1 diabetes: III. Predictors of 5–year urinary albumin excretion rate patterns in initially normoalbuminuric patients, Diabetes sourceExperimental — accuracy not yet measured

In the paper

“Cystatin C may also detect kidney dysfunction at an earlier stage than creatinine in people with diabetes (480).”

What the sources say

• Supported

  The Background says creatinine may rise only after substantial GFR loss and describes cystatin C as a promising marker for earlier detection of renal impairment. The Discussion likewise says cystatin C can rise faster than creatinine after GFR falls in patients with type 2 diabetes, supporting the claim's qualified wording. (LLM, conf=0.92)

  cites [480] Asmamaw, 2020, Early detection of renal impairment among patients with type 2 diabetes mellitus through evaluation of serum cystatin C in comparison with serum creatinine levels: a cross-sectional study, Diabetes Metab Syndr Obes source

In the paper

“The albumin-to-creatinine ratio is the best method to predict renal events in people with type 2 diabetes (490).”

What the sources say

• Partly supported

  The Abstract reports that the albumin-to-creatinine ratio from a first-morning void predicted renal events better than the other measures tested. However, the study examined patients with type 2 diabetes and nephropathy, not people with type 2 diabetes generally; the Discussion says its results cannot be directly applied to people without nephropathy. (LLM, conf=0.88)

  cites [490] Lambers Heerspink, 2010, Comparison of different measures of urinary protein excretion for prediction of renal events, J Am Soc Nephrol sourceExperimental — accuracy not yet measured

In the paper

“Adding cystatin C to serum creatinine improves the accuracy of race-neutral eGFR equations (476,477)”

What the sources say

• Supported

  The Discussion states that new race-free equations using both creatinine and cystatin C estimated measured GFR more accurately than equations using either marker alone. This directly supports the claim. (LLM, conf=0.94)

  cites [476] Inker, 2021, New creatinine- and cystatin C-based equations to estimate GFR without race, N Engl J Med source
• Partly supported

  The Results (Performance of New Equations in the Validation Data Set; page unavailable) report that the creatinine–cystatin C equation was more accurate than the creatinine-only equation. But the Results (Formulation of Equations; page unavailable) say adding race improved the combined equation’s performance, so the paper does not establish the claimed accuracy improvement specifically for race-neutral equations. (LLM, conf=0.90)

  cites [477] Inker, 2012, Estimating glomerular filtration rate from serum creatinine and cystatin C, N Engl J Med sourceExperimental — accuracy not yet measured

In the paper

“An important limitation of all these data is that the dipstick methods were compared with local laboratory methods, which, as indicated above, exhibit large biases (498).”

What the sources say

• Supported

  The Discussion reports that most routine urine-albumin measurement procedures had substantial biases, ranging from −35% to 34%, compared with IDMS. This supports the point for which the citation is offered—that laboratory methods can exhibit large biases. The paper does not itself report the dipstick comparisons described as context in the citing sentence. (LLM, conf=0.90)

  cites [498] Bachmann, 2014, State of the art for measurement of urine albumin: comparison of routine measurement procedures to isotope dilution tandem mass spectrometry, Clin Chem source

In the paper

“Given sufficiently sensitive techniques, insulin antibodies can be detected in any person being treated with exogenous insulin (518,519).”

What the sources say

• Partly supported

  The discussion of IAA related to other conditions (indexed as References; page not provided) says exogenous insulin may induce insulin-binding antibodies. It does not say antibodies are detectable in every person receiving exogenous insulin, even with sufficiently sensitive techniques. (LLM, conf=0.86)

  cites [518] Censi, 2018, Insulin autoimmune syndrome: from diagnosis to clinical management, Ann Transl Med sourceExperimental — accuracy not yet measured
• Partly supported

  The Introduction (page not specified) says exogenous insulin can induce insulin antibodies, including with human insulin. It does not say that sufficiently sensitive techniques can detect them in every person treated with exogenous insulin; it instead describes a reduced incidence with purified and recombinant preparations. (LLM, conf=0.86)

  cites [519] Hu, 2018, Exogenous insulin antibody syndrome (EIAS): a clinical syndrome associated with insulin antibodies induced by exogenous insulin in diabetic patients, Endocr Connect sourceExperimental — accuracy not yet measured

In the paper

“In most of these individuals, the titer of insulin antibodies is low, particularly in those who were never treated with animal insulins”

What the sources say

• Partly supported

  The passage on insulin antibodies related to other conditions (indexed under References; page unavailable) says antibodies induced by exogenous insulin are usually weak, broadly supporting the claim’s first part. It does not say their titers are low or that this is particularly true of people never treated with animal insulin. (LLM, conf=0.82)

  cites [518] Censi, 2018, Insulin autoimmune syndrome: from diagnosis to clinical management, Ann Transl Med sourceExperimental — accuracy not yet measured
• Supported

  The Introduction (page unavailable) describes high-titre insulin antibodies during human insulin or analogue treatment as sporadic and says human insulin induces antibodies less readily than animal insulin. The “Formulation of insulin” section (page unavailable) likewise states that animal insulin has higher immunogenicity. Together, these passages support the claim’s general comparison, although the paper does not give a numerical proportion with low titres. (LLM, conf=0.82)

  cites [519] Hu, 2018, Exogenous insulin antibody syndrome (EIAS): a clinical syndrome associated with insulin antibodies induced by exogenous insulin in diabetic patients, Endocr Connect source

In the paper

“and their presence is of no clinical significance.”

What the sources say

• Supported

  The passage on insulin antibodies induced by exogenous insulin (labeled References in our copy; page unavailable) says they are usually weak and that clinically significant effects occur in rare cases. This supports the claim’s qualification that their presence is generally of no clinical significance, rather than never significant. (LLM, conf=0.88)

  cites [518] Censi, 2018, Insulin autoimmune syndrome: from diagnosis to clinical management, Ann Transl Med source
• Supported

  The Clinical significance of IAs section says that clinically important glycaemic variability caused by insulin antibodies is very rare. The Conclusion says evidence of clinical effects is limited to case reports, supporting the claim that the antibodies have no clinical significance for most insulin-treated people, while acknowledging exceptions. The indexed copy provides section labels but no page numbers. (LLM, conf=0.86)

  cites [519] Hu, 2018, Exogenous insulin antibody syndrome (EIAS): a clinical syndrome associated with insulin antibodies induced by exogenous insulin in diabetic patients, Endocr Connect source

In the paper

“Measurement of the C-peptide, in the fasting state or in response to intravenous glucagon, can aid in instances in which it is difficult to differentiate between the diagnosis of type 1 and type 2 diabetes (5,511).”

What the sources say

• ?Could not verify

  The Loss of β-Cell Function section discusses insulin responses to intravenous glucose and other secretagogues, but not C-peptide testing for distinguishing type 1 from type 2 diabetes. Searches for C-peptide and diagnostic differentiation found no passage addressing that use; the indexed passages provide no page number. (LLM, conf=0.74)

  cites [5] Sacks, 1996, The pathogenesis of type II diabetes mellitus. A polygenic disease, Am J Clin Pathol sourceExperimental — accuracy not yet measured
• Supported

  The Diagnosis and Diabetes Classification section (page not provided) lists determining whether a patient has T1DM or T2DM as an indication for C-peptide measurement. The Conclusions section identifies both fasting and glucagon-stimulated C-peptide testing as available methods. (LLM, conf=0.93)

  cites [511] Leighton, 2017, A practical review of C-peptide testing in diabetes, Diabetes Ther source

In the paper

“Pooling results from a bivariate randomeffects model gave sensitivity and specificity estimates of 76% (95% CI, 63-86%) and 93% (CI, 84-97%), respectively, for the semiquantitative test (501).”

What the sources say

• ?Could not verify

  The Methods (Statistical Analyses; page unavailable) describe logistic prediction models whose estimates were combined by random-effects meta-analysis, not a bivariate diagnostic-accuracy model. A search for the semiquantitative test and the stated sensitivity and specificity found no passage reporting the 76% and 93% estimates or their confidence intervals. (LLM, conf=0.76)

  cites [501] Shin, 2021, Albuminuria testing in hypertension and diabetes: an individual-participant data meta-analysis in a global consortium, Hypertension sourceExperimental — accuracy not yet measured

In the paper

“Population studies have shown that fasting insulin concentration predicts future risk of ischemic heart disease events (507).”

What the sources say

• Supported

  The Abstract describes a prospective population study in which fasting insulin was measured before ischemic heart disease events occurred, and higher baseline concentrations were associated with subsequent events. The Discussion also reports that previous prospective studies found increased incidence with high fasting insulin in nondiabetic men. The passages provided do not include page numbers. (LLM, conf=0.93)

  cites [507] Després, 1996, Hyperinsulinemia as an independent risk factor for ischemic heart disease, N Engl J Med source

In the paper

“A cost-effectiveness analysis of 1,881 individuals with diabetes published in 2020 evaluated medical costs of CKD and concluded that the semiquantitative uACR dipstick method could be an appropriate screening tool for albuminuria in people with diabetes.”

What the sources say

• Supported

  The Results identify 1,881 patients with diabetes and report a cost-saving analysis that includes costs associated with end-stage renal disease. The Discussion concludes that the semi-quantitative method is eligible as an albuminuria screening tool for patients with diabetes and can reduce medical costs. Page numbers are not available in our copy. (LLM, conf=0.93)

  cites [503] Kim, 2020, Can a semi-quantitative method replace the current quantitative method for the annual screening of microalbuminuria in patients with diabetes? Diagnostic accuracy and cost-saving analysis considering the potential health burden, PLoS One source

In the paper

“Earlier studies may not have controlled well for undiagnosed diabetes, glycemic measures, BMI, or other confounders (507).”

What the sources say

• ?Could not verify

  The Discussion (page unavailable) says previous prospective studies did not identify insulin as an independent predictor after adjustment for other risk factors, but it does not say their control of confounding was inadequate. Matching Procedures describes this study’s matching on BMI and exclusion of men with reported diabetes; no passage found assesses earlier studies’ handling of undiagnosed diabetes, glycemic measures, BMI, or other confounders. (LLM, conf=0.75)

  cites [507] Després, 1996, Hyperinsulinemia as an independent risk factor for ischemic heart disease, N Engl J Med sourceExperimental — accuracy not yet measured

In the paper

“IUGR”

What the sources say

• Supported

  Table 2.6 (Future Considerations) lists IUGR as a clinical feature of KCNJ11-related neonatal diabetes and defines IUGR as intrauterine growth restriction. This supports the attributed claim. (LLM, conf=0.94)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“Permanent: IUGR; insulin requiring”

What the sources say

• Supported

  The Neonatal Diabetes section states that INS mutations are the second most common cause of permanent neonatal diabetes. Table 2.6 also lists permanent neonatal diabetes under INS. (LLM, conf=0.94)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“genitourinary”

What the sources say

• Supported

  Table 2.6 (Future Considerations) explicitly lists genitourinary abnormalities among the clinical features of HNF1B-MODY. The Maturity-Onset Diabetes of the Young section also associates HNF1B mutations or deletions with renal cysts and uterine malformations. (LLM, conf=0.95)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“responsive to sulfonylureas”

What the sources say

• Supported

  Table 2.6 (Future Considerations) lists ABCC8 under neonatal diabetes and describes it as responsive to sulfonylureas. The Neonatal Diabetes section also reports improved glycemic control with sulfonylureas in some people with KATP-related neonatal diabetes. (LLM, conf=0.95)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“However, on occasion high titers of insulin antibodies in the circulation can be associated with dramatic resistance to the ability of exogenous insulin to lower plasma glucose concentrations.”

What the sources say

• Supported

  The “Increased insulin resistance and risk of hyperglycaemia” section states that high insulin-antibody titres have been associated with insulin resistance and increased insulin requirements. It also says the antibodies can reduce insulin action and trigger hyperglycaemia; the “Characterization of IAs” section describes severe insulin resistance in EIAS. No page number is available in our copy. (LLM, conf=0.93)

  cites [519] Hu, 2018, Exogenous insulin antibody syndrome (EIAS): a clinical syndrome associated with insulin antibodies induced by exogenous insulin in diabetic patients, Endocr Connect source

In the paper

“IUGR”

What the sources say

• Supported

  Table 2.6 (Future Considerations) lists INS under neonatal diabetes and gives its clinical features as “Permanent: IUGR; insulin requiring.” The table defines IUGR as intrauterine growth restriction. (LLM, conf=0.94)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“responsive to sulfonylureas”

What the sources say

• Supported

  Table 2.6 (Future Considerations) lists KCNJ11 neonatal diabetes as “responsive to sulfonylureas.” The Neonatal Diabetes section also reports improved glycemic control with high-dose oral sulfonylureas in 30–50% of people with KATP-related neonatal diabetes. (LLM, conf=0.95)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“HNF1B-MODY: developmental renal disease”

What the sources say

• Supported

  Table 2.6 in the Future Considerations section lists “developmental renal disease (typically cystic)” as a clinical feature of HNF1B-MODY. The Maturity-Onset Diabetes of the Young section also associates HNF1B mutations or deletions with renal cysts. (LLM, conf=0.95)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“Permanent or transient: IUGR”

What the sources say

• Supported

  Table 2.6 (Future Considerations) lists ABCC8 under neonatal diabetes and describes its clinical features as “Permanent or transient: IUGR.” The Neonatal Diabetes section also identifies ABCC8 mutations as a common cause of permanent neonatal diabetes. (LLM, conf=0.94)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“developmental delay”

What the sources say

• Supported

  Table 2.6 (Future Considerations) lists ABCC8 under neonatal diabetes and describes developmental delay as rare. This directly supports the attributed claim. (LLM, conf=0.95)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“IUGR”

What the sources say

• Supported

  Table 2.6 (Future Considerations) lists IUGR among the clinical features of ABCC8-related neonatal diabetes, whether permanent or transient. The table defines IUGR as intrauterine growth restriction. (LLM, conf=0.93)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“insulin requiring”

What the sources say

• Supported

  Table 2.6 (shown under Future Considerations) lists INS-related neonatal diabetes as permanent and “insulin requiring.” The Neonatal Diabetes section also describes intensive insulin management as the preferred treatment strategy for INS mutations. (LLM, conf=0.95)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“and the cause-and-effect relationships between the magnitude of the increase in insulin antibodies and the degree of insulin resistance are unclear (519).”

What the sources say

• Supported

  In 'Clinical significance of IAs > Increased insulin resistance and risk of hyperglycaemia' (page not provided), the review associates high insulin-antibody levels with insulin resistance but says the mechanism underlying their causal relationship has not been clearly established. This supports the claim that the cause-and-effect relationship is unclear. (LLM, conf=0.90)

  cites [519] Hu, 2018, Exogenous insulin antibody syndrome (EIAS): a clinical syndrome associated with insulin antibodies induced by exogenous insulin in diabetic patients, Endocr Connect source

In the paper

“developmental delay and seizures”

What the sources say

• Supported

  Table 2.6 (Future Considerations) lists KCNJ11 neonatal diabetes with “possible developmental delay and seizures.” This directly supports the claim’s qualified wording; the supplied passage does not show a page number. (LLM, conf=0.95)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“Permanent or transient: IUGR”

What the sources say

• Supported

  Table 2.6 (Future Considerations) lists KCNJ11 under neonatal diabetes and identifies its clinical presentation as permanent or transient. The Neonatal Diabetes section also identifies KCNJ11 mutations as a common cause of permanent neonatal diabetes. (LLM, conf=0.94)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“gout”

What the sources say

• Supported

  Table 2.6 (Future Considerations) lists gout among the clinical features of HNF1B-MODY, alongside hyperuricemia and other features. (LLM, conf=0.95)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“pancreatic exocrine”

What the sources say

• Supported

  Table 2.6 (Future Considerations) lists pancreatic exocrine insufficiency among the clinical features of GATA6-related permanent neonatal diabetes. (LLM, conf=0.94)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“hernia”

What the sources say

• Supported

  Table 2.6 (Future Considerations) lists umbilical hernia among the clinical features of transient neonatal diabetes associated with 6q24. The Neonatal Diabetes section also identifies 6q24 overexpression as the most common cause of transient neonatal diabetes. (LLM, conf=0.94)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“Permanent: pancreatic hypoplasia; cardiac”

What the sources say

• Supported

  Table 2.6 (labeled Future Considerations in our copy; page not provided) lists GATA6 under neonatal diabetes and describes its clinical features as “Permanent: pancreatic hypoplasia; cardiac malformations.” This supports the attributed link between GATA6 mutations and permanent neonatal diabetes. (LLM, conf=0.94)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“Permanent: Wolcott-Rallison syndrome”

What the sources say

• Supported

  Table 2.6 (labeled Future Considerations in our copy; page not provided) lists EIF2AK3 under neonatal diabetes and identifies its permanent form as Wolcott–Rallison syndrome. This supports the attributed association. (LLM, conf=0.94)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“medications other than insulin”

What the sources say

• Supported

  The Neonatal Diabetes section says transient neonatal diabetes is most often due to overexpression of genes on chromosome 6q24 and may be treatable with medications other than insulin. Table 2.6 repeats this treatment qualification for 6q24-related transient neonatal diabetes. (LLM, conf=0.95)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“insulin requiring”

What the sources say

• Supported

  Table 2.6 (Future Considerations) lists GATA6 under neonatal diabetes and describes it as permanent and “insulin requiring.” (LLM, conf=0.95)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“6q24 (PLAGL1, HYMA1) | AD for paternal duplications”

What the sources say

• Supported

  Table 2.6 (Future Considerations) lists 6q24 (PLAGL1, HYMA1) with inheritance marked “AD for paternal duplications.” Its footnote defines AD as autosomal dominant, directly supporting the claim. (LLM, conf=0.95)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“pancreatic hypoplasia”

What the sources say

• Supported

  Table 2.6 (labeled Future Considerations in our copy) lists GATA6 under neonatal diabetes and names pancreatic hypoplasia as a clinical feature of the permanent form. This directly supports the attributed claim. (LLM, conf=0.94)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“Permanent: immunodysregulation,”

What the sources say

• Supported

  Table 2.6 (Future Considerations; page not supplied) lists FOXP3 under neonatal diabetes and identifies its X-linked form as permanent IPEX syndrome with autoimmune diabetes. The Neonatal Diabetes section defines neonatal diabetes as diabetes occurring before 6 months of age. (LLM, conf=0.91)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“fluctuating liver function”

What the sources say

• Supported

  The table of monogenic diabetes causes in Future Considerations explicitly lists EIF2B1 under permanent diabetes and says it can be associated with fluctuating liver function. The Neonatal Diabetes section also reports an EIF2B1 mutation associated with permanent neonatal diabetes and hepatic dysfunction. (LLM, conf=0.95)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“pancreatic exocrine”

What the sources say

• Supported

  The table in Future Considerations (page not provided) lists pancreatic exocrine insufficiency among the features of EIF2AK3-related Wolcott-Rallison syndrome. (LLM, conf=0.94)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“macroglossia”

What the sources say

• Supported

  Table 2.6 (Future Considerations) lists 6q24-related neonatal diabetes as transient and includes macroglossia among its clinical features. (LLM, conf=0.94)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“IUGR”

What the sources say

• Supported

  Table 2.6 (section labeled Future Considerations; page not provided) lists IUGR as a clinical feature of transient neonatal diabetes associated with 6q24. The table defines IUGR as intrauterine growth restriction. (LLM, conf=0.94)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“Permanent diabetes”

What the sources say

• Supported

  The Future Considerations table lists EIF2B1 among causes of monogenic diabetes and gives its clinical feature as “Permanent diabetes.” The Neonatal Diabetes section also reports an EIF2B1 mutation associated with permanent neonatal diabetes. (LLM, conf=0.92)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“insulin requiring”

What the sources say

• Supported

  The table of common causes of monogenic diabetes in Future Considerations lists Wolcott-Rallison syndrome under EIF2AK3 and explicitly describes it as “insulin requiring.” (LLM, conf=0.95)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source

In the paper

“Transient: IUGR; macroglossia; umbilical”

What the sources say

• Supported

  Table 2.6 (Future Considerations; page not provided) lists 6q24 (PLAGL1, HYMA1) under neonatal diabetes, identifies paternal duplications as an inheritance pattern, and describes the condition as transient. It also names paternal duplication as one of several mechanisms. (LLM, conf=0.94)

  cites [2] American Diabetes Association Professional Practice Committee, 2021, 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes—2022, Diabetes Care source